abdominal cramp/si [Side Effect]; alopecia/si [Side Effect]; aminotransferase blood level; analgesic activity; anorexia/si [Side Effect]; bone marrow suppression/si [Side Effect]; clinical outcome; combination drug therapy; diarrhea/si [Side Effect]; disease severity; dizziness/si [Side Effect]; drug cost; drug efficacy; drug formulation; drug safety; drug tolerability; dyslipidemia/si [Side Effect]; epigastric pain/si [Side Effect]; fatigue/si [Side Effect]; headache/si [Side Effect]; Hepatitis B virus; human; hypertension/si [Side Effect]; lactation; letter; liver fibrosis/si [Side Effect]; liver toxicity/si [Side Effect]; low drug dose; nausea/si [Side Effect]; neutropenia/si [Side Effect]; practice guideline; pregnancy; prevalence; rash/si [Side Effect]; rheumatoid arthritis/dt [Drug Therapy]; risk reduction; side effect/si [Side Effect]; stomatitis/si [Side Effect]; treatment duration; vaccination; virus reactivation; vomiting/si [Side Effect]; abatacept/ae [Adverse Drug Reaction]; abatacept/dt [Drug Therapy]; abatacept/iv [Intravenous Drug Administration]; abatacept/sc [Subcutaneous Drug Administration]; adalimumab/dt [Drug Therapy]; adalimumab/sc [Subcutaneous Drug Administration]; aminotransferase/ec [Endogenous Compound]; baricitinib/dt [Drug Therapy]; baricitinib/po [Oral Drug Administration]; celecoxib/dt [Drug Therapy]; certolizumab pegol/dt [Drug Therapy]; certolizumab pegol/sc [Subcutaneous Drug Administration]; corticosteroid/dt [Drug Therapy]; corticosteroid/ar [Intraarticular Drug Administration]; disease modifying antirheumatic drug/dt [Drug Therapy]; etanercept/dt [Drug Therapy]; etanercept/sc [Subcutaneous Drug Administration]; golimumab/dt [Drug Therapy]; golimumab/sc [Subcutaneous Drug Administration]; hydroxychloroquine/ae [Adverse Drug Reaction]; hydroxychloroquine/dt [Drug Therapy]; hydroxychloroquine/po [Oral Drug Administration]; hydroxychloroquine sulfate; infliximab/dt [Drug Therapy]; infliximab/iv [Intravenous Drug Administration]; Janus kinase inhibitor/dt [Drug Therapy]; leflunomide/ae [Adverse Drug Reaction]; leflunomide/dt [Drug Therapy]; leflunomide/po [Oral Drug Administration]; methotrexate/ae [Adverse Drug Reaction]; methotrexate/dt [Drug Therapy]; methotrexate/im [Intramuscular Drug Administration]; methotrexate/po [Oral Drug Administration]; methotrexate/sc [Subcutaneous Drug Administration]; nonsteroid antiinflammatory agent/dt [Drug Therapy]; rituximab/dt [Drug Therapy]; rituximab/iv [Intravenous Drug Administration]; salazosulfapyridine/ae [Adverse Drug Reaction]; salazosulfapyridine/dt [Drug Therapy]; salazosulfapyridine/po [Oral Drug Administration]; sarilumab/dt [Drug Therapy]; sarilumab/sc [Subcutaneous Drug Administration]; tocilizumab/ae [Adverse Drug Reaction]; tocilizumab/dt [Drug Therapy]; tocilizumab/iv [Intravenous Drug Administration]; tofacitinib/dt [Drug Therapy]; tofacitinib/po [Oral Drug Administration]; tumor necrosis factor inhibitor/dt [Drug Therapy]; upadacitinib/dt [Drug Therapy]; upadacitinib/po [Oral Drug Administration]; covid 19 vaccination; actemra actpen